Livforsakringsbolaget Skandia Omsesidigt Buys 17,100 Shares of Natera, Inc. $NTRA

Livforsakringsbolaget Skandia Omsesidigt increased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 213.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 25,095 shares of the medical research company’s stock after buying an additional 17,100 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Natera were worth $4,040,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in NTRA. Integrated Wealth Concepts LLC grew its holdings in shares of Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares in the last quarter. NewEdge Advisors LLC raised its stake in Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth lifted its position in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC bought a new stake in Natera during the second quarter worth about $298,000. Finally, Allworth Financial LP grew its stake in Natera by 29.6% during the second quarter. Allworth Financial LP now owns 1,453 shares of the medical research company’s stock worth $245,000 after buying an additional 332 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on NTRA shares. Wall Street Zen raised shares of Natera from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. BTIG Research lifted their price objective on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. Finally, Robert W. Baird raised their target price on Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a report on Friday, February 27th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $253.47.

Natera Stock Up 0.4%

NASDAQ NTRA opened at $198.38 on Wednesday. The company has a market cap of $28.12 billion, a price-to-earnings ratio of -129.66 and a beta of 1.65. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36. The business’s fifty day moving average is $217.92 and its 200 day moving average is $207.15.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. The business had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same quarter in the prior year, the firm earned ($0.41) EPS. On average, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Natera

In other news, insider John Fesko sold 707 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $204.13, for a total value of $144,319.91. Following the completion of the transaction, the insider owned 189,199 shares of the company’s stock, valued at $38,621,191.87. This represents a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Michael Burkes Brophy sold 785 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $204.13, for a total transaction of $160,242.05. Following the completion of the transaction, the chief financial officer owned 63,354 shares of the company’s stock, valued at approximately $12,932,452.02. This trade represents a 1.22% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 318,344 shares of company stock valued at $74,091,416. 5.63% of the stock is currently owned by company insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.